The prospect of a lawsuit against FDA has grown after the agency rejected three citizen petitions that requested a pathway to market for CBD in supplements.
Critics maintain the food ingredient GRAS program is broken, allowing manufacturers to circumvent FDA review and ultimately jeopardizing public health.